Major lupus organ involvement: Severe lupus nephritis

Lupus

Volumn 19, Issue 12, 2010, Pages 1391-1398

  Avihingsanon, Y ^a   Hirankarn, N ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Asia; genetic; immunosuppressive therapy; lupus nephritis

Indexed keywords

AZATHIOPRINE; CHEMOKINE RECEPTOR CXCR3; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CYCLOPHOSPHAMIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; STEROID; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

AREA UNDER THE CURVE; ASIAN; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG MEGADOSE; DRUG MONITORING; DRUG PULSE THERAPY; GENETIC PREDISPOSITION; HEREDITY; HERPES ZOSTER; HISTOLOGY; HUMAN; IMMUNOPATHOGENESIS; INFECTION; KIDNEY BIOPSY; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAINTENANCE THERAPY; OVARY INSUFFICIENCY; PATIENT MONITORING; PLASMAPHERESIS; PREVALENCE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; RECURRENCE RISK; RELAPSE; REVIEW; SCORING SYSTEM; SIGNAL TRANSDUCTION; SURVIVAL; T LYMPHOCYTE; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT;

ASIA; DISEASE PROGRESSION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LUPUS NEPHRITIS; RISK FACTORS;

EID: 78649730601     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310376522     Document Type: Review

References (58)

1. Boumpas DT, Austin 3rd HA, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992 ; 340: 741-745.
2. Parichatikanond P., Francis ND, Malasit P., et al. Lupus nephritis: clinicopathological study of 162 cases in Thailand. J Clin Pathol 1986 ; 39: 160-166.
3. Shayakul C., Ong-aj-yooth L., Chirawong P., et al. Lupus nephritis in Thailand: clinicopathologic findings and outcome in 569 patients. Am J Kidney Dis 1995 ; 26: 300-307.
4. Cameron JS, Turner DR, Ogg CS, et al. Systemic lupus with nephritis: a long-term study. Q J Med 1979 ; 48: 1-24.
5. Heller T., Ahmed M., Siddiqi A., Wallrauch C., Bahlas S. Systemic lupus erythematosus in Saudi Arabia: morbidity and mortality in a multiethnic population. Lupus 2007 ; 16: 908-914.
6. Kuiper-Geertsma DG, Derksen RH Newer drugs for the treatment of lupus nephritis. Drugs 2003 ; 63: 167-180.
7. Tikly M., Navarra SV Lupus in the developing world-is it any different? Best Pract Res Clin Rheumatol 2008 ; 22: 643-655.
8. Seligman VA, Lum RF, Olson JL, Li H., Criswell LA Demographic differences in the development of lupus nephritis: a retrospective analysis. Am J Med 2002 ; 112: 726-729.
9. Parichatikanond P., Chawanasuntorapoj R., Shayakul C., et al. An analysis of 3,555 cases of renal biopsy in Thailand. J Med Assoc Thai 2006 ; 89: S106 - S111.
10. Lee BS, Cho HY, Kim EJ, et al. Clinical outcomes of childhood lupus nephritis: a single center's experience. Pediatr Nephrol 2007 ; 22: 222-231.
11. Al Arfaj AS, Khalil N. Clinical and immunological manifestations in 624 SLE patients in Saudi Arabia. Lupus 2009 ; 18: 465-473.
12. Cheunsuchon B., Rungkaew P., Chawanasuntorapoj R., Pattaragarn A., Parichatikanond P. Prevalence and clinicopathologic findings of antiphospholipid syndrome nephropathy in Thai systemic lupus erythematosus patients who underwent renal biopsies. Nephrology 2007 ; 12: 474-480.
13. Yung S., Chan TM Anti-DNA antibodies in the pathogenesis of lupus nephritis-the emerging mechanisms. Autoimmun Rev 2008 ; 7: 317-321.
14. Tsirogianni A., Pipi E., Soufleros K. Relevance of anti-C1q auto-antibodies to lupus nephritis. Ann N Y Acad Sci 2009 ; 1173: 243-251.
15. Avihingsanon Y., Phumesin P., Benjachat T., et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int 2006 ; 69: 747-753.
16. Foster MH T cells and B cells in lupus nephritis. Semin Nephrol 2007 ; 27: 47-58.
17. Moser KL, Kelly JA, Lessard CJ, Harley JB Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 2009 ; 10 (5). 373-379.
18. Zheng L., Sinniah R., Hsu SI Renal cell apoptosis and proliferation may be linked to nuclear factor-kappaB activation and expression of inducible nitric oxide synthase in patients with lupus nephritis. Human Pathol 2006 ; 37: 637-647.
19. Pan Y., Sawalha AH Epigenetic regulation and the pathogenesis of systemic lupus erythematosus. Transl Res 2009 ; 153: 4-10.
20. Allam R., Pawar RD, Kulkarni OP, et al. Viral 5?-triphosphate RNA and non-CpG DNA aggravate autoimmunity and lupus nephritis via distinct TLR-independent immune responses. Eur J Immunol 2008 ; 38: 3487-3498.
21. Willcocks LC, Lyons PA, Clatworthy MR, et al. Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. J Exp Med 2008 ; 205: 1573-1582.
22. Nath SK, Han S., Kim-Howard X., et al. A nonsynonymous functional variant in integrin-αM (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet 2008 ; 40: 152-154.
23. Hom G., Graham RR, Modrek B., et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008 ; 358: 900-909.
24. Yang W., Zhao M., Hirankarn N., et al. ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai. Hum Mol Genet 2009 ; 18: 2063-2070.
25. Morel L. Genetics of human lupus nephritis. Semin Nephrol 2007 ; 27: 2-11.
26. Han JW, Zheng HF, Cui Y., et al. Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 2009 ; 41: 1234-1237.
27. Yang W., Shen N., Ye DQ, et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet 2010 ; 6: e1000841.
28. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med 1987 ; 83: 877-885.
29. Banfi G., Mazzucco G., Barbiano di Belgiojoso G., et al. Morphological parameters in lupus nephritis: their relevance for classification and relationship with clinical and histological findings and outcome. Q J Med 1985 ; 55: 153-168.
30. Austin 3rd HA, Boumpas DT, Vaughan EM, Balow JE Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994 ; 45: 544-550.
31. D'Agati V., Kunis C., Williams G., Appel GB Anti-cardiolipin antibody and renal disease: a report three cases. J Am Soc Nephrol 1990 ; 1: 777-784.
32. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004 ; 65: 521-530.
33. Avihingsanon Y., Benjachat T., Tassanarong A., Sodsai P., Kittikovit V., Hirankarn N. Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis. Kidney Int 2009 ; 75: 1340-1348.
34. Zabaleta-Lanz M., Vargas-Arenas RE, Tapanes F., Daboin I., Atahualpa Pinto J., Bianco NE Silent nephritis in systemic lupus erythematosus. Lupus 2003 ; 12: 26-30.
35. Austin 3rd HA, Klippel JH, Balow JE, et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986 ; 314: 614-619.
36. Austin HA, Boumpas DT Treatment of lupus nephritis. Semin Nephrol 1996 ; 16: 527-535.
37. Flanc RS, Roberts MA, Strippoli GF, Chadban SJ, Kerr PG, Atkins RC Treatment of diffuse proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis 2004 ; 43: 197-208.
38. Gourley MF, Austin 3rd HA, Scott D., et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med 1996 ; 125: 549-557.
39. Illei GG, Austin HA, Crane M., et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001 ; 135: 248-257.
40. Ong LM, Hooi LS, Lim TO, et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005 ; 10: 504-510.
41. Ponticelli C., Zucchelli P., Moroni G., Cagnoli L., Banfi G., Pasquali S. Long-term prognosis of diffuse lupus nephritis. Clin Nephrol 1987 ; 28: 263-271.
42. Houssiau FA, Vasconcelos C., D'Cruz D., et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002 ; 46: 2121-2131.
43. Balow JE Choosing treatment for proliferative lupus nephritis. Arthritis Rheum 2002 ; 46: 1981-1983.
44. Anthony C. Allison EME. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000 ; 47: 85-118.
45. van Bruggen MC, Walgreen B., Rijke TP, Berden JH Attenuation of murine lupus nephritis by mycophenolate mofetil. J Am Soc Nephrol 1998 ; 9: 1407-1415.
46. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000 ; 343: 1156-1162.
47. Bao H., Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008 ; 19: 2001-2010.
48. Traitanon O., Avihingsanon Y., Kittikovit V., et al. Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus 2008 ; 17: 744-751.
49. Austin HA, Balow JE Natural history and treatment of lupus nephritis. Semin Nephrol 1999 ; 19: 2-11.
50. Donadio Jr JV, Holley KE, Ferguson RH, Ilstrup DM Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978 ; 299: 1151-1155.
51. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004 ; 350: 971-980.
52. Chan TM, Tse KC, Tang CS, Mok MY, Li FK Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005 ; 16: 1076-1084.
53. Ponticelli C., Moroni G. Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus 1998 ; 7: 635-638.
54. Moroni G., Quaglini S., Maccario M., Banfi G., Ponticelli C. "Nephritic flares" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996 ; 50: 2047-2053.
55. Austin HA Clinical evaluation and monitoring of lupus kidney disease. Lupus 1998 ; 7: 618-621.
56. Chan RW, Tam LS, Li EK, et al. Inflammatory cytokine gene expression in the urinary sediment of patients with lupus nephritis. Arthritis Rheum 2003 ; 48: 1326-1331.
57. Appel GB, Contreras G., Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009 ; 20: 1103-1112.
58. Lertdumrongluk P., Somparn P., Kittanamongkolchai W., Traitanon O., Vadcharavivad S., Avihingsanon Y. Pharmacokinetics of mycophenolic acid in severe lupus nephritis. Kidney Int. 2010, Jun 9. [Epub ahead of print].